(NVS) Novartis AG Business Model Canvas Research

Novartis AG uses internal plants and external partners across raw materials, intermediates, packaging, and logistics to keep medicines moving worldwide. In 2025, Novartis reported net sales of about USD 50.3 billion, so supply uptime is material to revenue and patient access.

• Uses internal and external supply partners
• Covers materials, packaging, logistics
• Protects global product availability

Novartis works with regulators, public health systems, and reimbursement bodies in more than 100 markets, and these partners decide approval speed, price, and access. In 2025, that mattered across a portfolio that generated CHF 50.3 billion in net sales, so market access is a core value driver.

• Approvals shape launch timing
• Payers set access and pricing
• Regulation drives revenue pace

Novartis AG prepares global regulatory dossiers and keeps pharmacovigilance, labeling, and quality systems aligned across 100+ markets, because approvals and renewals depend on clean execution. In 2025, that work helped protect sales across a business that generated about $50 billion in annual revenue.

• Global dossiers for health authority review
• Safety, labeling, and quality compliance
• Supports approvals and continued sales

Novartis AG commercializes prescription medicines and generics across global markets, and in 2024 it reported net sales of USD 50.3 billion, showing how market access turns its portfolio into demand. It supports pricing, reimbursement, tendering, and product positioning so launches reach payers and patients fast.

• Global launch and promotion
• Pricing and reimbursement support
• Tender and payer execution
• Links portfolio to patient demand

Regulatory approvals and product dossiers are core assets for Novartis AG because they let the Company sell medicines across many countries and therapy areas. In 2024, Novartis reported net sales of US$50.3 billion, showing how much value depends on approved labels, filings, and compliance history.

• Market authorizations unlock country-level sales.
• Dossiers support new launches and renewals.
• Compliance history speeds future approvals.

Novartis AG depends on a large, specialized workforce of about 75,000 associates, and that human capital drives research, manufacturing, regulatory work, and sales. Its clinicians, chemists, engineers, and commercial teams turn a 2025 net sales base of about $50 billion into approved medicines and market execution.

• About 75,000 associates worldwide
• Specialists across R&D and manufacturing
• Commercial teams support launch execution

Novartis AG uses therapy development partnerships to bring its drug discovery, clinical, and manufacturing muscle to external partners, helping assets move faster and reach more patients. The Alnylam and Kura Oncology deals fit this model, while Novartis reported 2025 net sales of about $52.3 billion, showing the scale behind its partnership engine.

• Speeds development and regulatory work.
• Broadens pipeline reach with partners.
• Uses Novartis AG scale and expertise.
• Supports late-stage value creation.

Novartis AG sold products in over 100 markets in 2025, with global net sales of about USD 50.3 billion, so its distribution reach gives it scale across both developed and emerging healthcare systems. This wide network helps keep medicines available in more countries and supports faster commercial uptake.

• Over 100 markets served
• USD 50.3 billion 2025 net sales
• Supports broad product availability

Novartis keeps formal contact with regulators and scientific experts for filings, safety updates, and post-approval changes. In FY2025, Novartis reported net sales of $50.3 billion and invested $9.7 billion in R&D, showing how central regulatory and medical affairs are to a pipeline with 20+ major filings and lifecycle updates.

• Submissions and label changes
• Safety reporting and follow-up
• Health-authority and expert dialogue

Novartis AG uses B2B collaboration management to run long-term, contract-based alliances with partners like Alnylam and Kura. Joint teams track milestones, share data, and split commercialization duties, so governance stays tight across development and launch.

These partnerships matter because Novartis’ scale supports many external programs at once, with 2024 net sales of $50.3 billion and a strong pipeline tied to partnered science.

• Structured governance
• Joint milestone tracking
• Data-sharing rules
• Clear launch duties

Novartis uses digital and medical information platforms to educate on products, share disease-awareness content, and handle medical inquiries, while supporting face-to-face engagement. In 2024, Novartis reported net sales of US$50.3 billion, showing the scale behind these channels.

• Supports product education.
• Drives disease awareness.
• Handles medical inquiries online.
• Extends field-team reach.

Novartis AG uses partner commercialization routes to expand reach through networks it does not fully own, especially for shared assets like inclisiran. In 2025, inclisiran sales reached about US$1.8 billion, showing how partner-led launch and marketing can scale a medicine across markets fast.

• Partner networks widen market access.
• Licensing uses outside development and sales strength.
• Inclisiran is a key shared-asset example.

Government and private payers shape Novartis AG’s access to patients because they set reimbursement, pricing, and affordability rules. This matters at scale: Novartis AG reported about $50.3 billion in net sales in 2024, and public schemes, national health services, and private insurers can make or block that revenue path in each market.

• Set reimbursement terms
• Drive patient affordability
• Control market access
• Influence launch speed

Novartis AG serves pharmaceutical and biotech partners through licensing, co-development, and manufacturing deals, giving them access to development know-how, commercial reach, and biotech capability. This matters to its innovation engine, because partner-led programs help expand the pipeline while sharing risk and speeding scale.

• Licensing supports pipeline growth.
• Partners gain global commercial reach.
• Manufacturing adds biotech capacity.

Novartis AG carries a heavy regulatory load: global filings, safety monitoring, audits, and legal compliance create steady fixed costs plus variable spend tied to launches and label changes. In pharma, a miss can be costly fast: recalls, warning letters, and fines can hit cash flow, delay revenue, and force higher long-term compliance spend.

• Global filings raise fixed cost.
• Safety work adds ongoing spend.
• Noncompliance can trigger major losses.

Licensing and partnership commitments drive Novartis AG’s cost base through milestone fees, royalties, and shared development spend. In 2025, that matters more as partnered programs fund pipeline growth and keep commercialization rights, but they also lock Novartis AG into contractual expense exposure as deals progress.

• Milestones raise cash outflow on progress

• Royalties scale with partner sales

• Shared R&D cuts upfront risk

Novartis AG sells active pharmaceutical ingredients, intermediates, and some finished small-molecule drugs to other companies, so this B2B channel adds a second income line beside end-market sales. In 2025, the group still reported net sales in the CHF 50 billion-plus range, showing that these upstream and partner sales sit inside a very large base and help smooth revenue mix.

• Supplies APIs and intermediates
• Sells finished small-molecule drugs
• Diversifies income through B2B deals

Novartis AG uses licensing and milestone income to turn partnered science into cash, with upfront fees, development milestones, and royalties that can last for years. The Alnylam inclisiran deal is a clear example: Novartis booked a $150 million upfront payment and up to $2 billion in milestones plus royalties, showing how partnered assets can add long-duration upside.

• Upfront cash lowers funding risk
• Milestones tie pay to progress
• Royalties can scale for years